Clinical Trial Detail

NCT ID NCT04301011
Title Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors (RAPTOR)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Turnstone Biologics, Corp.
Indications

triple-receptor negative breast cancer

colorectal cancer

Advanced Solid Tumor

Therapies

TBio-6517

Pembrolizumab + TBio-6517

Age Groups: senior adult

No variant requirements are available.